Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study: second-generation antidepressants

20.09.2005


Because clinical depression is so disabling and affects more than 16 percent of adults in the United States at some time in their lives, researchers have worked hard to develop more effective treatments. But how much better are the newer pharmaceuticals?



Many second-generation antidepressants, despite differences in drug classification and cost, offer patients essentially the same benefits with little variation in risks, University of North Carolina at Chapel Hill researchers have found.

Such antidepressants include selective serotonin reuptake inhibitors (SSRIs) and other drugs that affect the activity of neurotransmitters in a selective way.


In a paper published online today (Sept. 19) and to be published in the October issue of the journal Annals of Internal Medicine, Dr. Richard A. Hansen and colleagues examined the effects of 10 commonly prescribed second-generation antidepressants. Those drugs included familiar brand-name drugs such as Prozac, Zoloft, Effexor, Wellbutrin and Paxil.

Hansen is assistant professor of pharmacy at the UNC School of Pharmacy. The study he led involved investigating the medications’ role in the initial treatment of adults suffering from major depression by combining and systematically analyzing data from 46 randomized, controlled trials.

Other authors, all at UNC, are Drs. Gerald Gartlehner and Timothy S. Carey of the Cecil G. Sheps Center for Health Services Research, Dr. Kathleen N. Lohr of the health policy and administration department at the School of Public Health, and Bradley N. Gaynes of the School of Medicine’s psychiatry department. Carey, professor of medicine, directs the Sheps Center. Gartlehner is associate director of the RTI-UNC Evidence-based Practice Center.

"Past studies have compared the effectiveness of second-generation antidepressants with that of placebo or older treatments but have not systematically evaluated how the second-generation agents compared to each other," Hansen said. "Given the number of second-generation treatments available, cost differences, widespread use and the general lack of consensus in how the drugs compare, our research can help patients, clinicians and policy makers decide which drug is best."

The bottom line was that one was about as good as another in terms of effectiveness, but the likelihood that patients experienced certain side effects differed between compounds, he said.

"Comparative evidence on these drugs suggests that there are only minimal differences in efficacy, although some of the drugs come with an increased risk of certain side effects," Hansen said. "Understanding the likelihood of the side effects and matching this information with patients’ lifestyle and preferences for anticipated side effects may help improve drug treatment of depression.

"Although our study did not specifically assess the impact of drug costs or differences in dosing regimens on how patients fared, those factors also may be important determinants in drug selection," the scientist said. "That’s in the absence of patient preference or a clear choice for which agent is best for a given person."

Limitations of the study were that published data from some trials was not as complete and comparable as researchers would have preferred, Hansen said. Most data was from trials sponsored by drug companies, and questions remain as to how unbiased such studies are.

Support for the investigation came to the Cecil G. Sheps Center for Health Services Research from the Drug Effectiveness Review Project, a collaborative program coordinated by the Center for Evidence-Based Policy at the Oregon Health and Science University.

In 2000, the economic burden of depression was estimated to be $83.1 billion, Hansen said. Although drug treatment does not work for all patients, drugs are usually considered the first and potentially best treatment in part since primary care physicians prescribe the majority of antidepressants in this country.

David Williamson | EurekAlert!
Further information:
http://www.unc.edu

More articles from Studies and Analyses:

nachricht New study: How does Europe become a leading player for software and IT services?
03.04.2017 | Fraunhofer-Institut für System- und Innovationsforschung (ISI)

nachricht Reusable carbon nanotubes could be the water filter of the future, says RIT study
30.03.2017 | Rochester Institute of Technology

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Fighting drug resistant tuberculosis – InfectoGnostics meets MYCO-NET² partners in Peru

28.04.2017 | Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

 
Latest News

Wireless power can drive tiny electronic devices in the GI tract

28.04.2017 | Medical Engineering

Ice cave in Transylvania yields window into region's past

28.04.2017 | Earth Sciences

Nose2Brain – Better Therapy for Multiple Sclerosis

28.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>